Recently, Laviana Pharma successfully passed the annual audit and CNAS expansion (Registration Number: CNAS L16763) to increase the scopes of many recognized tests as reviewed by the China National Accreditation Service for Conformity Assessment (CNAS), including pharmaceutical raw materials, intermediates and thermal safety testing of products, expanded to cover thermal safety testing of chemical products and pharmaceutical physicochemical testing. Among them, 1 test was expended in the thermal safety testing of chemical products, and 16 tests were expanded in the pharmaceutical physicochemical testing.

The review team conducted a detailed and comprehensive review from many aspects and angle by visiting the laboratory, viewing the system documents and observing the field practice. During the review, the experts of the review team presented professional by detailed comments and analysis on our testing and inspections. At the same time, the review team gave full recognition to Laviana Pharma’s management and technical competence.

The successful CNAS review and expansion demonstrate that Laviana Pharma has improved its recognized testing capabilities in the domestic and foreign industries, and the Tianjin R & D and Innovation Center have achieved a qualitative leap in management, technology, innovation and overall strength. Thus, the COAs issued by Laviana Pharma to customers are more credible. It is worth mentioning that the thermal analysis - thermal screening unit (TSU) is the first project certificated in China.

The CNAS expansion is another important measure of Laviana Pharma's strategic layout in the pharmaceutical field to expand a number of qualification capabilities, enhance our business scope, and provide customers with more high-quality services. In the future, Laviana Pharma will continue to provide high-quality testing services, provide one-stop CDMO comprehensive services for more domestic and foreign innovative pharmaceutical companies, and accelerate global pharmaceutical innovation.